- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| Fr | Elutia targets $20M EluPro revenue run rate and NXT-41 launch in H2 2026 while advancing hospital penetration | 1 | Seeking Alpha | ||
| Do | Elutia Q2 2025 slides: EluPro drives growth amid cash concerns | 2 | Investing.com | ||
| Do | Elutia Q2 2025: EluPro treibt Wachstum an, doch Liquidität gibt Anlass zur Sorge/n | 3 | Investing.com Deutsch | ||
| Do | Elutia GAAP EPS of -$0.23, revenue of $6.3M | 1 | Seeking Alpha | ||
| Do | ELUTIA INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Do | Elutia: EPS verfehlt Schätzungen um 0,07 $ - Umsatz schlechter als erwartet | - | Investing.com Deutsch | ||
| Do | Elutia reports 49% sequential growth in EluPro Q2 revenue | 1 | Investing.com | ||
| Do | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.07. | Elutia Inc.: Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award | 1 | GlobeNewswire (USA) | ||
| 01.07. | Elutia Inc.: New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices | 1 | GlobeNewswire (USA) | ||
| 04.06. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.06. | CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET | 2 | Investing.com | ||
| 28.05. | Elutia Inc.: Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method | 1 | GlobeNewswire (USA) | ||
| 13.05. | ELUTIA INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.05. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.05. | Elutia Inc.: Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio | 114 | GlobeNewswire (Europe) | Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting... ► Artikel lesen | |
| 01.05. | Elutia Inc.: Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 | 1 | GlobeNewswire (USA) | ||
| 21.04. | Elutia Inc.: Elutia Initiates EluPro Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | 1 | GlobeNewswire (USA) | ||
| 04.04. | Elutia Inc.: EluPro Named as 2025 Edison Award Winner | 2 | GlobeNewswire (USA) | ||
| 27.03. | Elutia Inc.: Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | -0,24 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen | |
| EVOTEC | 6,356 | -2,37 % | Evotec Aktie: Der Tag der Entscheidung naht | Bei der Evotec Aktie könnte es nun spannend werden, nicht nur wegen der morgen anstehenden Halbjahreszahlen. Zwar verharrt die Biotech-Aktie weiter in der seit Wochen etablierten Seitwärtsbewegung knapp... ► Artikel lesen | |
| DYNE THERAPEUTICS | 12,380 | -1,12 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,550 | +1,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BOLT PROJECTS | 8,910 | +4,82 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| BIONTECH | 97,00 | -0,05 % | BioNTech Aktie: Unterwegs zur großen Trendwende? | Die BioNTech Aktie befindet sich seit dem Jahrestief 2025 vom 7. April bei 81,20 Dollar in einem sekundären Aufwärtstrend. Trotz dieser Erholung blieb die Dynamik in den vergangenen Wochen verhalten... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,105 | -0,05 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| VALNEVA | 4,730 | -0,76 % | Valneva: Operativer Cashburn deutlich verringert - Umsatz steigt | Valneva hat im ersten Halbjahr 2025 die Gesamterlöse um 37,8 Prozent auf 97,6 Millionen Euro gesteigert. Der Umsatz aus Produktverkäufen stieg um 33,3 Prozent auf 91 Millionen Euro. Das Unternehmen... ► Artikel lesen | |
| IMMUNOME | 10,280 | +3,32 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| ARS PHARMACEUTICALS | 14,540 | +0,48 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| RECURSION PHARMACEUTICALS | 5,765 | +2,22 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,690 | +0,91 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 4,520 | +1,80 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| LENZ THERAPEUTICS | 37,870 | -7,43 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,820 | +3,33 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen |
ELUTIA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,040 Euro und damit -4,45 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.